Pharmacelera, CataloniaBio & HealthTech member that provides solutions for computer-aided drug design, has reached an agreement with the Institute of Biotechnology and Biomedicine (IBB) of the Universitat Autònoma de Barcelona to perform a research project in the area of Parkinson based in the alpha-synucleic protein.
"The in silico selection technologies will be a key complement to our experimental approach" Dr Salvador Ventura, director of IBB-UAB, points out.
Pharmacelera's CEO Enric Gibert explains "we are sure that our flagship software PharmScreen® will play a key role in proposing new candidates for the treatment of Parkinson's disease."
Esteve, the University of Barcelona, the California Institute for Biomedical Research, Redx Pharma, among others, are using the technology of Pharmacelera.
Comments